By Chris Wack
MAIA Biotechnology's shares rose 19% to $2.46 after the company said it entered into a clinical supply agreement with BeiGene to evaluate THIO, MAIA's telomere-targeting anticancer agent.
The clinical-stage biopharmaceutical company said THIO will be used alongside BeiGene's tislelizumab in three cancer types: hepatocellular carcinoma, small cell lung cancer, and colorectal cancer.
The trials will test the combination's efficacy in single-arm Phase 2 studies.
MAIA will fund and sponsor the trials, retaining global rights to THIO while BeiGene supplies tislelizumab. The Chicago-based company is trying to get accelerated Food and Drug Administration approvals for these indications.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 07, 2025 13:05 ET (18:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.